A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Terminated · Phase 2 · NCT04916002
Conditions: Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer, Oropharynx Squamous Cell Carcinoma
At a glance
- Research payments reported, 2025
- $1.4M
- U.S. investigators named
- 15
- Sites paid
- 15
- Planned or actual enrollment
- 77
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- vidutolimod (drug), cemiplimab (drug)
- Dates
- Started 2021-11-30; completion 2024-10-31
- Results posted
- Yes
The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer. The main questions it aims to answer are: * How many participants' cancers respond to vidutolimod together with cemiplimab? * Is vidutolimod together with cemiplimab safe and well-tolerated? * How well does vidutolimod together with cemiplimab treat participants' cancer? Participants will receive trial treatment for up to 2 years. 30 days after stopping treatment, participants will have a follow-up visit. After that visit, the trial staff will continue to follow up with participants about every 3 months, until the trial ends.
From ClinicalTrials.gov, last updated 2026-06-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $1.4M in research payments for this study in 2025 (1,345 payments).
Products named: Libtayo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Deborah J. Wong, M.D., PH.D. Hematology & Oncology · Los Angeles, CA
- Tirrell T. Johnson, MD Medical Oncology · Orlando, FL
- Douglas E. Laux, MD Hematology & Oncology · Iowa City, IA
- Jaspreet S. Grewal, M.D., M.P.H. Hematology & Oncology · Louisville, KY
- Ann W. Silk, M.D. Medical Oncology · Boston, MA
- Ammar Sukari, M.D. Medical Oncology · Detroit, MI
- Nasreen A. Vohra, M.D. Surgical Oncology · Greenville, NC
- Keisuke Shirai, MD Hematology & Oncology · Lebanon, NH
- Andrew L. Pecora, MD Medical Oncology · Hackensack, NJ
- Ciara M. Kelly, MB BCH BAO Medical Oncology · New York, NY
- Soojin Park, MD Neurology · New York, NY
- Richard C. Wu, M.D., PH.D. Medical Oncology · Columbus, OH
- Diwakar Davar Hematology & Oncology · Pittsburgh, PA
- Julio A. Peguero, M.D Medical Oncology · Corpus Christi, TX
- Shailender Bhatia, MD Medical Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Washington Medical Ctr, WA $271,049
- The Ohio State University $235,763
- East Carolina University $182,098
- Hackensack University Medical Center, NJ $154,501
- Regents of the University of California $140,771
- University of Pittsburgh $110,870
- Memorial Sloan Kettering Cancer Center $97,848
- University of Iowa Hospital & Clinics, IA $53,965
- Orlando Health, FL $45,507
- Karmanos Cancer Center, MI $19,106
- Norton Healthcare Inc $16,096
- Dana Farber Mass General Brigham Cancer Care Inc $10,461
- Ronald Reagan UCLA Medical Center, CA $10,353
- Oncology Consultants PA $9,874
- Dartmouth Hitchcock Clinic $7,020
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.